Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta

Oncology September 27,2024 0

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta

Oncology September 27,2024 0

Sex matters in how, when, and where melanomas develop

byElsevierFitted temporal trend of invasive cutaneous melanoma incidence (1982- 2018) for males vs. females from three populations (Queensland, US Whites, Scotland), by body site. Credit:J

Dermatology September 27,2024 0

Sex matters in how, when, and where melanomas develop

byElsevierFitted temporal trend of invasive cutaneous melanoma incidence (1982- 2018) for males vs. females from three populations (Queensland, US Whites, Scotland), by body site. Credit:J

Dermatology September 27,2024 0

New multimodal signature could predict immunotherapy success

byUniversity of InnsbruckCredit:iScience(2024). DOI: 10.1016/j.isci.2024.110529An international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC)

Oncology September 27,2024 0

New multimodal signature could predict immunotherapy success

byUniversity of InnsbruckCredit:iScience(2024). DOI: 10.1016/j.isci.2024.110529An international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC)

Oncology September 27,2024 0

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi

Oncology September 27,2024 0

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi

Oncology September 27,2024 0

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can

Oncology September 27,2024 0

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can

Oncology September 27,2024 0

Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-

Oncology September 27,2024 0

Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-

Oncology September 27,2024 0

Elle Macpherson says she refused chemotherapy after breast cancer diagnosis—here's what oncologists think

byUniversity of VirginiaCredit: Pixabay/CC0 Public DomainAfter being diagnosed with breast cancer seven years ago, Elle Macpherson made a controversial choice: She refused chemotherapy, the mode

Oncology September 27,2024 0

Elle Macpherson says she refused chemotherapy after breast cancer diagnosis—here's what oncologists think

byUniversity of VirginiaCredit: Pixabay/CC0 Public DomainAfter being diagnosed with breast cancer seven years ago, Elle Macpherson made a controversial choice: She refused chemotherapy, the mode

Oncology September 27,2024 0

Palliative low-dose radiotherapy improves pain in hepatic cancer

by Elana GotkineFor adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone, according to

Oncology September 27,2024 0

Palliative low-dose radiotherapy improves pain in hepatic cancer

by Elana GotkineFor adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone, according to

Oncology September 27,2024 0

Preclinical study finds novel bone cancer therapy has 99% success rate

byAston UniversityProfessor Richard Martin. Credit: Aston UniversityBioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined

Oncology September 27,2024 0

Preclinical study finds novel bone cancer therapy has 99% success rate

byAston UniversityProfessor Richard Martin. Credit: Aston UniversityBioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined

Oncology September 27,2024 0

Pollution exposure may affect lung cancer in women who have never smoked

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainRecent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may sign

Oncology September 27,2024 0

Pollution exposure may affect lung cancer in women who have never smoked

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainRecent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may sign

Oncology September 27,2024 0